The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

MG Vilia, E Fonte, T Veliz Rodriguez, M Tocchetti, P Ranghetti, L Scarfò, N Papakonstantinou, S Ntoufa, K Stamatopoulos, P Ghia, M Muzio

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies. © 2017 Informa UK Limited, trading as Taylor & Francis Group
Original languageEnglish
Pages (from-to)2419-2425
Number of pages7
JournalLeukemia and Lymphoma
Volume58
Issue number10
DOIs
Publication statusPublished - 2017

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Interleukin-8
Down-Regulation
Inflammation
Azacitidine
Interleukin-1 Receptors
DNA Methylation
Neoplasms
Leukemia
Proteins
B-Lymphocytes
Messenger RNA
Therapeutics

Cite this

The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. / Vilia, MG; Fonte, E; Veliz Rodriguez, T; Tocchetti, M; Ranghetti, P; Scarfò, L; Papakonstantinou, N; Ntoufa, S; Stamatopoulos, K; Ghia, P; Muzio, M.

In: Leukemia and Lymphoma, Vol. 58, No. 10, 2017, p. 2419-2425.

Research output: Contribution to journalArticle

Vilia, MG, Fonte, E, Veliz Rodriguez, T, Tocchetti, M, Ranghetti, P, Scarfò, L, Papakonstantinou, N, Ntoufa, S, Stamatopoulos, K, Ghia, P & Muzio, M 2017, 'The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia', Leukemia and Lymphoma, vol. 58, no. 10, pp. 2419-2425. https://doi.org/10.1080/10428194.2017.1295142
Vilia, MG ; Fonte, E ; Veliz Rodriguez, T ; Tocchetti, M ; Ranghetti, P ; Scarfò, L ; Papakonstantinou, N ; Ntoufa, S ; Stamatopoulos, K ; Ghia, P ; Muzio, M. / The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 10. pp. 2419-2425.
@article{683992f09ac24a0cab07e5c2e596b019,
title = "The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia",
abstract = "Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies. {\circledC} 2017 Informa UK Limited, trading as Taylor & Francis Group",
author = "MG Vilia and E Fonte and {Veliz Rodriguez}, T and M Tocchetti and P Ranghetti and L Scarf{\`o} and N Papakonstantinou and S Ntoufa and K Stamatopoulos and P Ghia and M Muzio",
year = "2017",
doi = "10.1080/10428194.2017.1295142",
language = "English",
volume = "58",
pages = "2419--2425",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

AU - Vilia, MG

AU - Fonte, E

AU - Veliz Rodriguez, T

AU - Tocchetti, M

AU - Ranghetti, P

AU - Scarfò, L

AU - Papakonstantinou, N

AU - Ntoufa, S

AU - Stamatopoulos, K

AU - Ghia, P

AU - Muzio, M

PY - 2017

Y1 - 2017

N2 - Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies. © 2017 Informa UK Limited, trading as Taylor & Francis Group

AB - Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies. © 2017 Informa UK Limited, trading as Taylor & Francis Group

U2 - 10.1080/10428194.2017.1295142

DO - 10.1080/10428194.2017.1295142

M3 - Article

VL - 58

SP - 2419

EP - 2425

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -